Sponsor: Summit Therapeutics
Sponsor Study ID: SMT112-3003
Study Title: A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)
CTO #: 103876
NCT Number: NCT05899608
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung
Study Objectives: To compare overall survival (OS) between ivonescimab combined with carboplatin and paclitaxel or nab-paclitaxel versus pembrolizumab combined with carboplatin and paclitaxel or nab-paclitaxel